Bessemer Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bessemer Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-45,800	Closed	-$1.17M	–	1514
2020 Q2	$1.17M	Buy	+45,800	New	+$957K	﹤0.01%	705

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bessemer Group's KNSA Position: Q3 2020 in Review

Bessemer Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2020, closing a stake of 45,800 shares — an estimated $1.17M sold.

Bessemer Group first reported a position in KNSA in Q2 2020 and held it in 1 quarter. The position peaked at $1.17M in Q2 2020. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2020.

Bessemer Group reported no remaining Kiniksa Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bessemer Group sold 45,800 Kiniksa Pharmaceuticals shares in Q3 2020, an estimated $1.17M.
Bessemer Group first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Bessemer Group's Kiniksa Pharmaceuticals position peaked at $1.17M in Q2 2020.
104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.